Widad Group Bhd has signed a memorandum of collaboration with Rinani Dynamic Sdn Bhd in relation to the distribution, marketing and sale of oral Covid-19 vaccine tablet developed by US-based Vaxart Inc.
Rinani is the local representative in Malaysia for Nasdaq-listed Vaxart, with respect to its ongoing development of an oral based Covid-19 vaccine named VXA-Cov2-1. The appointment of Rinani was made by Majoritas Global Limited, a company incorporated in Hong Kong, who in turn is Vaxart’s global representative for Malaysia.
Under the agreement, Rinani will be collaborating with Widad in the distribution, marketing and selling of the vaccine and other Vaxart products in Malaysia. Widad stated that it is ready to support Rinani Dynamics objective of ensuring that people of Malaysia would be among the first to receive Vaxart’s vaccine, when it receives the FDA and EUA clearance for commercialisation. The vaccine candidate is expected to be entering Phase II of clinical trials.